journal
https://read.qxmd.com/read/38591430/combination-of-dasatinib-and-venetoclax-in-newly-diagnosed-chronic-phase-chronic-myeloid-leukemia
#1
JOURNAL ARTICLE
Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, Jeffrey Skinner, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Ghayas C Issa, Michael Andreeff, Hagop Kantarjian
BACKGROUND: The dual inhibition of the BCR::ABL1 tyrosine kinase and BCL-2 could potentially deepen the response rates of chronic myeloid leukemia in chronic phase (CML-CP). This study evaluated the safety and efficacy of the combination of dasatinib and venetoclax. METHODS: In this phase 2 trial, patients with CML-CP or accelerated phase (clonal evolution) received dasatinib 50 mg/day for three courses; venetoclax was added in course 4 for 3 years. The initial venetoclax dose was 200 mg/day continuously but reduced later to 200 mg/day for 14 days, and to 100 mg/day for 7 days per course once a molecular response (MR)4...
April 9, 2024: Cancer
https://read.qxmd.com/read/38581695/prognostic-impact-of-number-of-induction-courses-to-attain-complete-remission-in-patients-with-acute-myeloid-leukemia-transplanted-with-either-a-matched-sibling-or-human-leucocyte-antigen-10-10-or-9-10-unrelated-donor-an-acute-leukemia-working-party-european
#2
JOURNAL ARTICLE
Justin Loke, Myriam Labopin, Charles Craddock, Gérard Socié, Tobias Gedde-Dahl, Didier Blaise, Edouard Forcade, Urpu Salmenniemi, Anne Huynh, Jurjen Versluis, Ibrahim Yakoub-Agha, Hélène Labussière-Wallet, Johan Maertens, Jakob Passweg, Claude Eric Bulabois, Ludovic Gabellier, Stephan Mielke, Cristina Castilla-Llorente, Eric Deconinck, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
INTRODUCTION: For the majority of patients with acute myeloid leukemia (AML) an allogeneic stem cell transplant (SCT) in first complete remission (CR) is preferred. However, whether the number of courses required to achieve CR has a prognostic impact is unclear. It is unknown which factors remain important in patients requiring more than one course of induction to attain remission. METHODS: This Acute Leukaemia Working Party study from the European Society for Blood and Marrow Transplantation identified adults who received an allograft in first CR from either a fully matched sibling or 10/10 or 9/10 human leucocyte antigen (HLA)-matched unrelated donor (HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ)...
April 6, 2024: Cancer
https://read.qxmd.com/read/38581694/dose-intensified-stereotactic-body-radiotherapy-for-painful-vertebral-metastases-a-randomized-phase-3-trial
#3
JOURNAL ARTICLE
Matthias Guckenberger, Charlotte Billiet, Daniel Schnell, Ciro Franzese, Mateusz Spałek, Susanne Rogers, Jean-Jacques Stelmes, Daniel M Aebersold, Hossein Hemmatazad, Frank Zimmermann, Jörg Zimmer, Thomas Zilli, Alessio Bruni, Brigitta G Baumert, Franziska Nägler, Philipp Gut, Robert Förster, Indira Madani
BACKGROUND: The purpose of this randomised study was to determine whether dose-intensified stereotactic body radiotherapy (SBRT) for painful vertebral metastases results in increased rates of pain improvement compared with conventional external beam radiotherapy (cEBRT) (control) 6 months after treatment. METHODS: This randomized, controlled phase 3 trial was conducted between November 2016 and January 2023, when it was stopped early. Patients were eligible if they were aged 18 years or older; had one or two painful, stable, or potentially unstable vertebral metastases; and had a life expectancy of 1 year or longer according to the investigator's estimates...
April 6, 2024: Cancer
https://read.qxmd.com/read/38579107/body-composition-and-late-occurring-chronic-health-conditions-after-autologous-stem-cell-transplantation-for-lymphoma
#4
JOURNAL ARTICLE
Smith Giri, Christian Harmon, Wendy Landier, Yanjun Chen, Jessica Wu, Lindsey Hageman, Nora Balas, Liton Francisco, Alysia Bosworth, Daniel J Weisdorf, Stephen J Forman, Saro H Armenian, Grant R Williams, Smita Bhatia
BACKGROUND: Autologous peripheral blood stem cell transplantation (aPBSCT) is the standard of care for adults with relapsed lymphoma, yet recipients remain at risk of developing chronic health conditions (CHCs). It was hypothesized that body composition measurements of skeletal muscle and fat are associated with late-onset CHCs and nonrelapse mortality after aPBSCT. METHODS: Leveraging the Blood or Marrow Transplant Survivor Study, we examined association between pre-aPBSCT body composition and new-onset grade 3-5 CHCs among 187 adults with lymphoma treated with aPBSCT (2011-2014) surviving ≥2 years after aPBSCT...
April 5, 2024: Cancer
https://read.qxmd.com/read/38578983/top-advances-of-the-year-gastroesophageal-cancer
#5
JOURNAL ARTICLE
Karyn A Goodman, Alexandra Hotca, Mengyuan Liu, Vivian E Strong, David H Ilson
No abstract text is available yet for this article.
April 5, 2024: Cancer
https://read.qxmd.com/read/38578977/impact-of-tocilizumab-on-anti-cd19-chimeric-antigen-receptor-t-cell-therapy-in-b-cell-acute-lymphoblastic-leukemia
#6
JOURNAL ARTICLE
Xiangmin Wang, Bingpei Zhang, Qing Zhang, Hongyuan Zhou, Qian Sun, Yi Zhou, Tianci Li, Dian Zhou, Ziyuan Shen, Jiaoli Zhang, Ping Li, Aibin Liang, Keshu Zhou, Lu Han, Yongxian Hu, Yun Yang, Jiang Cao, Zhenyu Li, Kailin Xu, Wei Sang
BACKGROUND: Tocilizumab is commonly used for the management of chimeric antigen receptor (CAR) T-cell therapy-associated cytokine release syndrome (CRS). However, it remains unknown whether tocilizumab or its dosage affects the efficacy and safety of CAR T-cell therapy. The objective of this multicenter retrospective study was to explore the impact of tocilizumab on CAR T-cell therapy. METHODS: In total, 93 patients with B-cell acute lymphoblastic leukemia (B-ALL) receiving humanized anti-CD19 CAR T cells were recruited from May 2016 to November 2022...
April 5, 2024: Cancer
https://read.qxmd.com/read/38567689/the-need-for-multilevel-supportive-care-infrastructure-for-cancer-caregivers
#7
EDITORIAL
Kelly M McConnell, Megan J Shen
No abstract text is available yet for this article.
April 3, 2024: Cancer
https://read.qxmd.com/read/38567685/-to-prescribe-or-not-to-prescribe-that-is-the-question-perspectives-on-opioid-prescribing-for-chronic-cancer-related-pain-from-clinicians-who-treat-pain-in-survivorship
#8
JOURNAL ARTICLE
Hailey W Bulls, Megan Hamm, Julia Wasilewski, Donna Olejniczak, Sarah G Bell, Jane M Liebschutz
BACKGROUND: Opioid pain management in cancer survivorship is a complex and understudied topic. METHODS: The authors conducted in-depth, qualitative interviews to understand clinician approaches to opioid pain management in chronic cancer pain and to generate ideas for improvement. They used a rigorous, inductive, qualitative, descriptive approach to examine clinician (n = 20) perspectives about opioid pain management in survivorship, including oncologists (n = 5), palliative care clinicians (n = 8), primary care clinicians (n = 5), and pain management specialists (n = 2)...
April 3, 2024: Cancer
https://read.qxmd.com/read/38567652/embryonal-sarcoma-of-the-liver-in-pediatric-and-young-adult-patients-a-report-from-children-s-oncology-group-study-arst0332
#9
JOURNAL ARTICLE
Sheri L Spunt, Wei Xue, Zhengya Gao, Andrea Hayes Dixon, Lynn Million, Stephanie F Polites, Sanjeev A Vasudevan, Simon C Kao, M Beth McCarville, David M Parham, Donald A Barkauskas, Zhongjie Cai, Carrye Cost, Leo Mascarenhas, Aaron R Weiss
BACKGROUND: Embryonal sarcoma of the liver (ESL) is a rare mesenchymal tumor most common in childhood; the optimal treatment approach is uncertain. The clinical features and outcomes of patients with ESL enrolled in a Children's Oncology Group (COG) clinical trial that evaluated a risk-based strategy for treating soft tissue sarcomas in patients aged <30 years were evaluated. METHODS: This subset analysis included patients with ESL enrolled in COG study ARST0332...
April 3, 2024: Cancer
https://read.qxmd.com/read/38564338/electronic-health-intervention-to-manage-symptoms-of-immunotherapy-in-patients-with-cancer-sofia-results-from-a-randomized-controlled-pilot-trial
#10
JOURNAL ARTICLE
Christina Sauer, Stefanie Zschäbitz, Jürgen Krauss, Thomas Walle, Georg Martin Haag, Dirk Jäger, Kiriaki Hiller, Till Johannes Bugaj, Hans-Christoph Friederich, Imad Maatouk
BACKGROUND: For patients receiving immune checkpoint inhibitors, early detection of immune-related adverse events (irAEs) is critical for one's safety. To this end, a smartphone app (SOFIA) was developed that featured the assessment of electronic patient-reported outcomes (ePROs) focusing on irAEs as well as a set of comprehensive supportive information. Its feasibility and preliminary efficacy were evaluated in a randomized controlled trial (RCT). METHODS: Patients who received immune checkpoint inhibition therapy were randomly assigned to an intervention group (IG) or a control group (CG; care as usual)...
April 2, 2024: Cancer
https://read.qxmd.com/read/38564301/cabozantinib-with-immune-checkpoint-inhibitor%C3%A2-versus-cabozantinib-monotherapy-in-patients-with-metastatic-clear-cell-renal-cell-carcinoma-progressing-after-prior-immune-checkpoint-inhibitor
#11
JOURNAL ARTICLE
Georges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, Haoran Li, Nicolas Sayegh, Nishita Tripathi, Ayana Srivastava, Blake Nordblad, Emre Dal, Arshit Narang, James Brundage, Patrick Campbell, Gliceida Galarza Fortuna, Chadi Hage Chehade, Benjamin L Maughan, Neeraj Agarwal, Umang Swami
INTRODUCTION: Rechallenge with antibodies targeting programmed cell death protein-1 or its ligand (PD-1/L1) after discontinuation or disease progression in solid tumors following a prior PD-1/L1 treatment is often practiced in clinic. This study aimed to investigate if adding PD-1/L1 inhibitors to cabozantinib, the most used second-line treatment in real-world patients with metastatic clear cell renal cell carcinoma (mccRCC), offers additional benefits. METHODS: Using de-identified patient-level data from a large real-world US-based database, patients diagnosed with mccRCC, who received any PD-1/L1-based combination in first-line (1L) setting, followed by second-line (2L) therapy with either cabozantinib alone or in combination with PD-1/L1 inhibitors were included...
April 2, 2024: Cancer
https://read.qxmd.com/read/38554271/uses-and-limitations-of-artificial-intelligence-for-oncology
#12
REVIEW
Likhitha Kolla, Ravi B Parikh
Modern artificial intelligence (AI) tools built on high-dimensional patient data are reshaping oncology care, helping to improve goal-concordant care, decrease cancer mortality rates, and increase workflow efficiency and scope of care. However, data-related concerns and human biases that seep into algorithms during development and post-deployment phases affect performance in real-world settings, limiting the utility and safety of AI technology in oncology clinics. To this end, the authors review the current potential and limitations of predictive AI for cancer diagnosis and prognostication as well as of generative AI, specifically modern chatbots, which interfaces with patients and clinicians...
March 30, 2024: Cancer
https://read.qxmd.com/read/38552145/curing-pediatric-cancer-a-global-view-examples-from-acute-lymphoblastic-leukemia
#13
JOURNAL ARTICLE
Caitlyn Duffy, Stephen P Hunger, Nickhill Bhakta, Avram E Denburg, Federico Antillon, Ronald D Barr
No abstract text is available yet for this article.
March 29, 2024: Cancer
https://read.qxmd.com/read/38549441/symptomatic-androgen-deficiency-and-sexual-dysfunctions-in-male-patients-receiving-alectinib-for-alk-positive%C3%A2-advanced-nonsmall-cell-lung-cancer
#14
JOURNAL ARTICLE
Emanuele Vita, Federico Monaca, Domenico Milardi, Luca Mastrantoni, Alessio Stefani, Edoardo Vergani, Jacopo Russo, Diletta Barone, Ileana Sparagna, Antonio Vitale, Alessandro Scala, Denis Occhipinti, Mariantonietta Di Salvatore, Alfredo Pontecorvi, Giampaolo Tortora, Emilio Bria
BACKGROUND: It is reported that treatment with anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) induces hypogonadism both in male patients with ALK-positive cancer and in murine models. METHODS: In this study, three groups, including an experimental group of male patients with ALK-positive, advanced nonsmall cell lung cancer (ANSCLC) who were receiving alectinib (cohort A), a control group of female patients with ALK-positive ANSCLC who were receiving alectinib (cohort B), and a control group of male patients with ALK-negative ANSCLC (cohort C), prospectively underwent a full hormone assessment for androgen deficiency at 8 weeks after the start of treatment and in case of reported suspected symptoms...
March 28, 2024: Cancer
https://read.qxmd.com/read/38547206/erratum-to-expert-consensus-based-guidance-on-approaches-to-opioid-management-in-individuals-with-advanced-cancer-related-pain-and-nonmedical-stimulant-use
#15
(no author information available yet)
No abstract text is available yet for this article.
March 28, 2024: Cancer
https://read.qxmd.com/read/38546445/implementation-enrollment-and-engagement-in-an-opt-out-telehealth-pharmacist-assisted-tobacco-treatment-program-for-patients-seen-in-oncology-outpatient-clinics
#16
JOURNAL ARTICLE
K Michael Cummings, Benjamin A Toll, Vincent Talbot, Avery Roberson, Dianne Wilson, Martha Dunlap, Emily C Ware, Amanda M Palmer, Asia A Bliss, Vincent S Anokye, Graham Warren
OBJECTIVE: To describe the workflow, reach, cost, and self-reported quit rates for an opt-out tobacco treatment program (TTP) for patients seen in 43 oncology outpatient clinics. METHODS: Between May 25, 2021, and December 31, 2022, adult patients (≥18 years) visiting clinics affiliated with the Medical University of South Carolina Hollings Cancer Center were screened for smoking status. Those currently smoking were referred to a telehealth pharmacy-assisted TTP...
March 28, 2024: Cancer
https://read.qxmd.com/read/38529676/significance-of-hiv-status-in-cervical-cancer-patients-receiving-curative-chemoradiation-therapy-definitive-radiation-alone-or-palliative-radiation-in-botswana
#17
JOURNAL ARTICLE
Kinza Meghani, Priya Puri, Lisa Bazzett-Matabele, Peter Vuylsteke, Rebecca Luckett, Barati Monare, Sebathu Chiyapo, Rebecca Ketlametswe, Tlotlo B Ralefala, Memory Bvochora-Nsingo, Nicola Zetola, Doreen Ramogola-Masire, Surbhi Grover
BACKGROUND: Cervical cancer associated with human papillomavirus has the highest cancer incidence and mortality for women in Botswana because of a high HIV prevalence and limited screening. This study investigates the significance of HIV on the overall survival (OS) of patients with locally advanced cervical cancer by various treatment categories (curative chemoradiation, definitive radiation [RT] alone, or palliative RT alone). METHODS: This study included patients diagnosed with cervical cancer between 2013 and 2020, prospectively enrolled in the Botswana Prospective Cancer Cohort...
March 26, 2024: Cancer
https://read.qxmd.com/read/38529566/a-practical-guide-for-assessing-and-managing-cardiovascular-risk-during-androgen-deprivation-therapy-in-patients-with-prostate-cancer
#18
REVIEW
Aum J Solanki, Mitchell Kamrava, Edwin M Posadas, Stephen J Freedland, Leslie Ballas, Howard M Sandler, C Noel Bairey Merz, Katelyn M Atkins, Andriana P Nikolova
Prostate cancer is the most common malignancy among men worldwide, and androgen-deprivation therapy (ADT) is a mainstay of treatment. There are observational data demonstrating an increased risk of cardiovascular events in patients who receive ADT, particularly those who have an elevated baseline cardiovascular risk. Because, for most patients with prostate cancer, death is predominantly from noncancer-related causes, cardiovascular disease and its risk factors should be optimized during cancer treatment. This review provides an overview of the landscape of ADT treatment and serves as a guide for appropriate cardiovascular screening and risk-mitigation strategies...
March 26, 2024: Cancer
https://read.qxmd.com/read/38525946/breast-cancer-therapy-in-china-introducing-the-special-collection
#19
EDITORIAL
Xiaojia Wang, Ruth M O'Regan
No abstract text is available yet for this article.
March 25, 2024: Cancer
https://read.qxmd.com/read/38523461/factors-contributing-to-differences-in-cervical-cancer-screening-in-rural-and-urban-community-health-centers
#20
JOURNAL ARTICLE
Hyunjung Lee, Jordan Baeker Bispo, Parichoy Pal Choudhury, Daniel Wiese, Ahmedin Jemal, Farhad Islami
INTRODUCTION: Community health centers (CHCs) provide historically marginalized populations with primary care, including cancer screening. Previous studies have reported that women living in rural areas are less likely to be up to date with cervical cancer screening than women living in urban areas. However, little is known about rural-urban differences in cervical cancer screening in CHCs and the contributing factors, and whether such differences changed during the COVID-19 pandemic...
March 25, 2024: Cancer
journal
journal
20067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.